PLA2R1 mediates tumor suppression by activating JAK2.

Little is known about the physiological role of the phospholipase A2 receptor (PLA2R1). PLA2R1 has been described as regulating the replicative senescence, a telomerase-dependent proliferation arrest. The downstream PLA2R1 signaling and its role in cancer are currently unknown. Senescence induction in response to activated oncogenes is a failsafe program of tumor suppression that must be bypassed for tumorigenesis. We now present evidence that PLA2R1 functions in vitro as a tumor suppressor, the depletion of which is sufficient to escape oncogene-induced senescence (OIS), thereby facilitating oncogenic cell transformation. Furthermore, mice that are genetically deficient in PLA2R1 display increased sensitivity to RAS-induced tumorigenesis by facilitating OIS escape, highlighting its physiological role as a tumor suppressor. Unexpectedly, PLA2R1 activated JAK2 and its effector signaling, with PLA2R1-mediated inhibition of cell transformation largely reverted in JAK2-depleted cells. This finding was unexpected as the JAK2 pathway has been associated mainly with protumoral functions and several inhibitors are currently in clinical trials. Taken together, our findings uncover an unanticipated tumor suppressive role for PLA2R1 that is mediated by targeting downstream JAK2 effector signaling.

[1]  D. Peeper,et al.  Senescence-messaging secretome: SMS-ing cellular stress , 2009, Nature Reviews Cancer.

[2]  David F Jarrard,et al.  Therapy-induced senescence in cancer. , 2010, Journal of the National Cancer Institute.

[3]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[4]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[5]  K. Kiguchi,et al.  Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications , 2009, Nature Protocols.

[6]  Frédérick A. Mallette,et al.  DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. , 2006, Molecular biology of the cell.

[7]  F. Schaper,et al.  Regulation of rat heme oxygenase-1 expression by interleukin-6 via the Jak/STAT pathway in hepatocytes. , 2006, Journal of hepatology.

[8]  J. Bartek,et al.  Cytokine expression and signaling in drug-induced cellular senescence , 2010, Oncogene.

[9]  M. Mann,et al.  A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties* , 2000, The Journal of Biological Chemistry.

[10]  K. Nakajima,et al.  The STAT3-IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts , 2012, Cell cycle.

[11]  J. Clohessy,et al.  Pro-senescence therapy for cancer treatment , 2011, Nature Reviews Cancer.

[12]  Kwang Seok Kim,et al.  Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  H. Kantarjian,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond , 2011, Nature Reviews Drug Discovery.

[14]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[15]  T. Kishimoto,et al.  Signaling mechanisms through cytokine receptors that share signal transducing receptor components. , 1995, Current opinion in immunology.

[16]  M. Serrano,et al.  Senescence in tumours: evidence from mice and humans , 2010, Nature Reviews Cancer.

[17]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[18]  P. Adams.  Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. , 2009, Molecular cell.

[19]  D. Bernard,et al.  The M‐type receptor PLA2R regulates senescence through the p53 pathway , 2009, EMBO reports.

[20]  A. Verma,et al.  Jak family of kinases in cancer , 2003, Cancer and Metastasis Reviews.

[21]  E. Hexner.  JAK2 V617F: implications for thrombosis in myeloproliferative diseases , 2007, Current opinion in hematology.

[22]  Kei Yamamoto,et al.  Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. , 2010, Biochimie.

[23]  S. Okugawa,et al.  Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. , 2003, American journal of physiology. Cell physiology.

[24]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[25]  Simon Tavaré,et al.  Autophagy mediates the mitotic senescence transition. , 2009, Genes & development.

[26]  C. Pecquet,et al.  Mining for JAK-STAT mutations in cancer. , 2008, Trends in biochemical sciences.

[27]  B. Williams,et al.  Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis , 2003, Apoptosis.

[28]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[29]  D. Peeper,et al.  The essence of senescence. , 2010, Genes & development.

[30]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[31]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[32]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[33]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[34]  J. Campisi,et al.  Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo , 2009, Nature Protocols.

[35]  Takafumi Yoshida,et al.  The N-terminal Truncated Isoform of SOCS3 Translated from an Alternative Initiation AUG Codon under Stress Conditions Is Stable Due to the Lack of a Major Ubiquitination Site, Lys-6* , 2003, The Journal of Biological Chemistry.

[36]  H. Arita,et al.  Resistance to Endotoxic Shock in Phospholipase A2 Receptor-deficient Mice* , 1997, The Journal of Biological Chemistry.

[37]  Z. Estrov,et al.  The JAK-STAT pathway: a therapeutic target in hematological malignancies. , 2006, Current cancer drug targets.

[38]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[39]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[40]  P. Stahl,et al.  The mannose receptor is a pattern recognition receptor involved in host defense. , 1998, Current opinion in immunology.

[41]  K. Muta,et al.  Loss of Jak2 Selectively Suppresses DC-Mediated Innate Immune Response and Protects Mice from Lethal Dose of LPS-Induced Septic Shock , 2010, PloS one.

[42]  A. Skalka,et al.  Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[43]  O. Llorca.  Extended and bent conformations of the mannose receptor family , 2008, Cellular and Molecular Life Sciences.

[44]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[45]  I. Gresser.  Antitumor effects of interferon. , 1978, Advances in cancer research.

[46]  J. Bartek,et al.  Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling , 2010, Cell cycle.